Synergistic and chemosensitizing effects of bovine lactoferrin or muramyl dipeptide in Ehrlich solid tumor-bearing mice treated with cisplatin

Document Type : Original Article


1 Zoology Department, Faculty of Science, Menoufia University, Shibin El-Kom, Egypt

2 Immunology and Biotechnology Division, Department of Zoology, Faculty of Science, Tanta University, Egypt


Background: Despite the effectiveness of anti-cancer chemotherapy, it is associated with serious adverse side effects and the development of drug-resistance mechanisms. Immune dysfunction is considered one of the most serious adverse effects of anti-cancer chemotherapy, which increases the susceptibility of the patients to infection. Co-administration of immunomodulatory agents as adjuvant therapy with chemotherapy will result in better anti-tumor responses with fewer side effects. Aim: This study was designed to evaluate the ameliorative effects of bovine lactoferrin (bLF) and muramyl dipeptide (MDP) against toxicity induced by cisplatin in tumor-bearing mice. Materials and Methods: In this study, MDP or bLF was co-treated with cisplatin in mice bearing Ehrlich solid tumor (EST). Results: Co- treatment of cisplatin with MDP or bLF enhanced the anti-tumor effects of cisplatin to induce a reduction of the tumor size, proliferative capabilities of tumor cells accompanied by an elevation in the apoptotic profile of tumor cells. Moreover, co- treatments of Cisplatin with bLF or MDP reversed the Cisplatin-induced immune suppression and partially restored splenocyte proliferation, immune organ indices, hematological profile, liver and kidney functions, and histological structure. Conclusion: Both bLF and MDP were able to act as adjuvant therapy with anti-cancer chemotherapy through their abilities to enhance the chemotherapy curative effects, modulate the immune response against tumor cells, and to some extent ameliorate the adverse toxic effects of the chemotherapy.


Main Subjects